JOP20200016B1 - أجسام مضادة لـ cd137 - Google Patents
أجسام مضادة لـ cd137Info
- Publication number
- JOP20200016B1 JOP20200016B1 JOP/2020/0016A JOP20200016A JOP20200016B1 JO P20200016 B1 JOP20200016 B1 JO P20200016B1 JO P20200016 A JOP20200016 A JO P20200016A JO P20200016 B1 JOP20200016 B1 JO P20200016B1
- Authority
- JO
- Jordan
- Prior art keywords
- antibodies
- chemotherapy
- bind
- human
- useful
- Prior art date
Links
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 102000050327 human TNFRSF9 Human genes 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
يتعلق الاختراع الحالي بأجسام مضادة ترتبط مع CD137 البشري ويكون لها نشاط مساعد، ويمكن الاستفادة منها في علاج الأورام الصلبة والدموية بمفردها وفي توليفة مع علاج كيميائي وإشعاع مؤين.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762539687P | 2017-08-01 | 2017-08-01 | |
PCT/US2018/043632 WO2019027754A1 (en) | 2017-08-01 | 2018-07-25 | ANTI-CD137 ANTIBODIES |
Publications (2)
Publication Number | Publication Date |
---|---|
JOP20200016A1 JOP20200016A1 (ar) | 2020-01-28 |
JOP20200016B1 true JOP20200016B1 (ar) | 2022-10-30 |
Family
ID=63165504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0016A JOP20200016B1 (ar) | 2017-08-01 | 2018-07-25 | أجسام مضادة لـ cd137 |
Country Status (22)
Country | Link |
---|---|
US (1) | US10906983B2 (ar) |
EP (2) | EP3661544B1 (ar) |
JP (2) | JP6743320B1 (ar) |
KR (2) | KR102344620B1 (ar) |
CN (1) | CN111182919B (ar) |
AU (2) | AU2018311804B2 (ar) |
BR (1) | BR112020001441A2 (ar) |
CA (2) | CA3071383C (ar) |
CL (1) | CL2020000233A1 (ar) |
CO (1) | CO2020001050A2 (ar) |
CR (1) | CR20200042A (ar) |
DO (1) | DOP2020000020A (ar) |
EA (1) | EA202090204A1 (ar) |
EC (1) | ECSP20007663A (ar) |
ES (1) | ES2912651T3 (ar) |
IL (1) | IL272349B1 (ar) |
JO (1) | JOP20200016B1 (ar) |
MA (1) | MA49749A (ar) |
MX (1) | MX2020001351A (ar) |
PH (1) | PH12020500225A1 (ar) |
SG (1) | SG11202000747VA (ar) |
WO (1) | WO2019027754A1 (ar) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019027754A1 (en) * | 2017-08-01 | 2019-02-07 | Eli Lilly And Company | ANTI-CD137 ANTIBODIES |
US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
KR20200035966A (ko) | 2017-07-11 | 2020-04-06 | 콤파스 테라퓨틱스 엘엘씨 | 인간 cd137에 결합하는 작동자 항체 및 이의 용도 |
WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
AU2019237977A1 (en) * | 2018-03-23 | 2022-01-20 | Eli Lilly And Company | Anti-CD137 antibodies for combination with anti-PD-1 antibodies |
MX2020009863A (es) * | 2018-03-23 | 2021-01-08 | Lilly Co Eli | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1. |
US11939381B2 (en) * | 2018-07-19 | 2024-03-26 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
AU2020308463A1 (en) * | 2019-06-26 | 2022-02-17 | Ap Biosciences, Inc. | Antibodies for T-cell activation |
TW202144395A (zh) * | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
EP4253530A1 (en) | 2020-11-25 | 2023-10-04 | Shanghai Juncell Therapeutics Co., Ltd. | Tumor infiltration lymphocyte culture medium and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2328025T3 (es) * | 2001-10-09 | 2009-11-06 | Mayo Foundation For Medical Education And Research | Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb. |
US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
RU2710717C2 (ru) * | 2010-09-09 | 2020-01-10 | Пфайзер Инк. | Молекулы, связывающиеся с 4-1ВВ |
CN107921104A (zh) | 2015-02-22 | 2018-04-17 | 索伦托治疗有限公司 | 结合cd137的抗体疗法 |
GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
WO2019027754A1 (en) * | 2017-08-01 | 2019-02-07 | Eli Lilly And Company | ANTI-CD137 ANTIBODIES |
-
2018
- 2018-07-25 WO PCT/US2018/043632 patent/WO2019027754A1/en unknown
- 2018-07-25 KR KR1020207002814A patent/KR102344620B1/ko active IP Right Grant
- 2018-07-25 US US16/497,493 patent/US10906983B2/en active Active
- 2018-07-25 KR KR1020217041897A patent/KR20210158420A/ko not_active Application Discontinuation
- 2018-07-25 EP EP18752950.8A patent/EP3661544B1/en active Active
- 2018-07-25 BR BR112020001441-9A patent/BR112020001441A2/pt unknown
- 2018-07-25 EA EA202090204A patent/EA202090204A1/ru unknown
- 2018-07-25 CN CN201880064332.2A patent/CN111182919B/zh active Active
- 2018-07-25 EP EP22159268.6A patent/EP4070811A1/en not_active Withdrawn
- 2018-07-25 IL IL272349A patent/IL272349B1/en unknown
- 2018-07-25 CA CA3071383A patent/CA3071383C/en active Active
- 2018-07-25 JO JOP/2020/0016A patent/JOP20200016B1/ar active
- 2018-07-25 JP JP2020505392A patent/JP6743320B1/ja active Active
- 2018-07-25 CR CR20200042A patent/CR20200042A/es unknown
- 2018-07-25 SG SG11202000747VA patent/SG11202000747VA/en unknown
- 2018-07-25 MA MA049749A patent/MA49749A/fr unknown
- 2018-07-25 ES ES18752950T patent/ES2912651T3/es active Active
- 2018-07-25 AU AU2018311804A patent/AU2018311804B2/en active Active
- 2018-07-25 MX MX2020001351A patent/MX2020001351A/es unknown
- 2018-07-25 CA CA3146758A patent/CA3146758A1/en active Pending
-
2020
- 2020-01-29 CO CONC2020/0001050A patent/CO2020001050A2/es unknown
- 2020-01-29 CL CL2020000233A patent/CL2020000233A1/es unknown
- 2020-01-30 PH PH12020500225A patent/PH12020500225A1/en unknown
- 2020-01-31 EC ECSENADI20207663A patent/ECSP20007663A/es unknown
- 2020-01-31 DO DO2020000020A patent/DOP2020000020A/es unknown
- 2020-07-29 JP JP2020128427A patent/JP7257364B2/ja active Active
-
2021
- 2021-12-02 AU AU2021277707A patent/AU2021277707A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500225A1 (en) | Anti- cd137 antibodies | |
PH12019500369A1 (en) | Anti-tim-3 antibodies | |
PH12019501253A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies | |
MY199019A (en) | Pd-1 antibodies | |
PH12019502875A1 (en) | Antibody molecules to cd73 and uses thereof | |
PH12019501393A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
TN2018000044A1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
MX2020006668A (es) | Anticuerpos para lilrb2. | |
PH12020500075A1 (en) | Checkpoint inhibitor bispecific antibodies | |
MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
MX2021014472A (es) | Moleculas de union a tigit y pd-1/tigit. | |
PH12019502313A1 (en) | Anti-pd-l1-anti-tim-3 bispecific antibodies | |
MX2020009864A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1. | |
MX2020009863A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1. |